Y-mabs announces complete response letter for omburtamab biologics license application

New york, dec. 01, 2022 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the u.s. food and drug administration (“fda”) has issued a complete response letter (“crl”) for the biologics license application (“bla”) for the investigational medicine 131i-omburtamab (“omburtamab”) for the treatment of cns/leptomeningeal metastasis from neuroblastoma.
YMAB Ratings Summary
YMAB Quant Ranking